AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,377,733 | +117.7% | 126,092 | +101.0% | 0.01% | +166.7% |
| Q2 2023 | $2,929,611 | +32.0% | 62,746 | +8.1% | 0.00% | 0.0% |
| Q1 2023 | $2,219,922 | -22.7% | 58,022 | +10.7% | 0.00% | -25.0% |
| Q4 2022 | $2,872,726 | +404.0% | 52,422 | +174.1% | 0.00% | +300.0% |
| Q3 2022 | $570,000 | +7.3% | 19,122 | -23.8% | 0.00% | – |
| Q4 2021 | $531,000 | -5.3% | 25,102 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $561,000 | +4.3% | 25,102 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $538,000 | -26.1% | 25,102 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $728,000 | +43.9% | 25,102 | +28.0% | 0.00% | 0.0% |
| Q4 2020 | $506,000 | +5.4% | 19,605 | +25.6% | 0.00% | 0.0% |
| Q3 2020 | $480,000 | +121.2% | 15,605 | +78.9% | 0.00% | – |
| Q2 2020 | $217,000 | -5.2% | 8,722 | -15.5% | 0.00% | – |
| Q4 2019 | $229,000 | -2.6% | 10,322 | 0.0% | 0.00% | – |
| Q3 2019 | $235,000 | – | 10,322 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 1,621,829 | $75,723,196 | 32.88% |
| COMMODORE CAPITAL LP | 1,675,000 | $78,205,750 | 8.79% |
| Ghost Tree Capital, LLC | 360,000 | $16,808,400 | 5.55% |
| Boxer Capital, LLC | 1,676,733 | $78,287 | 3.63% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 241,357 | $11,268,958 | 3.49% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $27,745,579 | 3.45% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 236,500 | $11,039,820 | 3.42% |
| Logos Global Management LP | 520,000 | $24,278,800 | 3.30% |
| Redmile Group, LLC | 1,811,672 | $84,586,966 | 3.25% |
| Yiheng Capital Management, L.P. | 1,201,591 | $56,102,284 | 3.03% |